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BirOBJECTIVES This study used a large national cohort to examine patterns of thrombectomy use in ST-segment
elevation myocardial infarction (STEMI) and the relationship to mortality.
BACKGROUND The impact of coronary thrombectomy on mortality in STEMI has not been deﬁnitively established.
Published trial data have been insufﬁciently powered to address this.
METHODS The U.K. national registry was used to study 98,176 patients treated with primary percutaneous coronary
intervention (PCI), between January 1, 2006, and December 31, 2013. Patients were grouped on the basis of whether they
received thrombectomy or not; subgroups of simple (manual aspiration) and complex (mechanical) thrombectomy were
also evaluated. The primary endpoint was 30-day mortality. The principal adjusted analysis used propensity score
matching (PSM). A sensitivity analysis was performed using logistic regression controlled for the propensity score.
RESULTS Thrombectomy use markedly increased in the United Kingdom between 2008 and 2010 but plateaued
thereafter at slightly below 50% of all primary PCI cases. No signiﬁcant mortality difference was seen, in adjusted an-
alyses, between the overall thrombectomy group and the no thrombectomy group, at 30 days or 1 year (at 30 days, PSM
average treatment effect [ATE] coefﬁcient 0.0028, 95% conﬁdence interval: 0.0048 to 0.0104; p ¼ 0.47). Likewise,
no difference was seen between the simple (manual) thrombectomy versus no thrombectomy, at either time point (at 30
days, PSM ATE coefﬁcient 0.0007, 95% conﬁdence interval: 0.0049 to 0.0063; p ¼ 0.80). By contrast, the complex
(mechanical) thrombectomy group demonstrated a signiﬁcantly higher mortality than the no thrombectomy group at
1-year follow-up (PSM ATE coefﬁcient 0.0434, 95% conﬁdence interval: 0.0081 to 0.0786; p ¼ 0.017).
CONCLUSIONS Coronary thrombectomy was not associated with lower mortality in primary PCI for STEMI when used
in our large all-comer cohort in a selective manner on the basis of physician judgment. These ﬁndings are consistent with
other negative clinical outcomes in recent large randomized controlled trials studying routine manual thrombectomy in
primary PCI. (J Am Coll Cardiol Intv 2016;9:126–34) © 2016 by the American College of Cardiology Foundation.m the *Department of Cardiology, University College London Hospitals and St. Bartholomew’s Hospital, London, United
gdom; yCardiovascular Research Group, Institutes of Science and Technology in Medicine and Primary Care, University of
ele and Farr Institute and Institute of Cardiovascular Sciences, University of Manchester, United Kingdom; zInstitute for
pulation Health, University of Manchester, Manchester, United Kingdom; xDepartment of Cardiology,QueenElizabethHospital,
mingham,UnitedKingdom; and the kDepartment of Cardiology, Brighton and Sussex University Hospitals, Royal Sussex
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grafting
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PCI = percutaneous coronary
intervention
PPCI = primary percutaneous
coronary intervention
RCT = randomized controlled
trial
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
ardial Infarction
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127P rimary percutaneous coronary intervention(PPCI) has become the treatment of choicefor ST-segment elevation myocardial infarc-
tion (STEMI). Attempts to minimize distal emboliza-
tion of thrombus led to the development of
thrombectomy devices for use before angioplasty or
stenting. These devices are broadly classiﬁed into
simple (manual aspiration) or complex (mechanical
aspiration, with or without prior fragmentation),
with the former most widely used in clinical practice.
Small early trials with various aspiration catheters
yielded encouraging results but were underpowered
to study major adverse cardiovascular events (1,2).
The larger TAPAS (Thrombus Aspiration during
Percutaneous coronary intervention in Acute myocar-
dial infarction Study) found an unanticipated, size-
able mortality advantage at 1 year from manual
aspiration thrombectomy (3), and a subsequent
meta-analysis in 2013 continued to support this
notion of reduced mortality with thrombectomy useSEE PAGE 135(4). Since then, results from the randomized TASTE
(Thrombus Aspiration in Myocardial Infarction) trial
have cast doubt over the value of routine manual
thrombectomy in STEMI (5,6). However, the much
lower-than-anticipated event rate represents a major
caveat in interpreting mortality ﬁndings from the
TASTE trial (7). The TOTAL (A Trial of Routine Aspira-
tion Thrombectomy With Percutaneous Coronary
Intervention [PCI] Versus PCI Alone in Patients With
ST-Segment Elevation Myocardial Infarction [STEMI]
Undergoing Primary PC) study (with event-driven
trial completion) has now also shown no signiﬁcant
improvement in any hard clinical endpoints
(including death) by 180 days with routine thrombec-
tomy use (8). There was a trend towards reduction in
cardiovascular mortality at 30 days favoring throm-
bectomy use (hazard ratio: 0.83, 95% conﬁdence in-
terval: 0.65 to 1.06), but this did not achieve
statistical signiﬁcance. As the TOTAL authors had
recognized in advance, a trial with adequate power
to conclusively demonstrate (or refute) an impact on
all-cause mortality with thrombectomy would have
required in excess of 30,000 patients and was there-
fore judged to be impractical (9). Hence, larger ran-
domized controlled trials (RCTs) with adequate
power to detect a mortality beneﬁt from thrombec-
tomy use are unlikely, and an alternative approachCounty Hospital, Brighton, United Kingdom. The authors have reported that t
this paper to disclose. Drs. Sirker and Mamas have contributed equally to th
Manuscript received September 11, 2015; accepted October 22, 2015.is warranted. Such information could inﬂu-
ence clinical practice, because thrombectomy
use is by no means “the norm” worldwide—
for example, it was utilized in only around
20% of PPCI cases in a survey of >1,000 hos-
pitals in the United States during 2009 to
2010 (10). Its use appears set to decline
further in the light of results from the
TOTAL study.
The U.K.–British Cardiovascular Interven-
tion Society (BCIS) cohort has several major
strengths, making the information it can
provide complementary to that gained from
recent RCTs on thrombectomy. First, very
large patient numbers confer statistical po-
wer to speciﬁcally study the unresolved
question about a mortality beneﬁt associated
with thrombectomy use. Second, as a regis-
try, it naturally includes higher-risk patients who are
frequently excluded from RCTs—this is relevant
because one explicit limitation in the TOTAL study
was the lack of screening log records, making gener-
alizability of the study’s outcomes to all-comers
somewhat harder to ascertain. Third, another
inherent limitation in TOTAL was the mandated use
of thrombectomy in the active treatment arm—
thereby removing the potential impact of physician
judgment to direct its use to cases where it might be
of greatest beneﬁt and to avoid its use where there
was greatest risk of harm. By contrast, our work
provides insight into the impact of selective use of
thrombectomy on clinical outcomes in an all-comer
primary PPCI population, and it is therefore highly
pertinent to real-world practice.
METHODS
U.K. NATIONAL PCI DATABASE. U.K. PCI data are
collected by the BCIS and overseen by the National
Institute of Cardiovascular Outcomes Research
(NICOR). The dataset records PCI procedures per-
formed in any hospital within the United Kingdom.
Further detailed information regarding data collec-
tion processes, data validation, and handling of
missing data has been published previously (11).
The BCIS-NICOR database records clinical, proce-
dural, and outcome information with a total of 113
variables. The Medical Research Information Service
collects mortality information by linking patients’
Myochey have no relationships relevant to the contents of
is work.
FIGURE 1 Participant Flow Diagram
An indication of the numbers of patients involved in the study and reasons for patient
exclusion are shown. See text for further details. *Missingness across variables is not
mutually exclusive (e.g., sex and age might be missing for a case). BCIS ¼ British
Cardiovascular Intervention Society; PCI ¼ percutaneous coronary intervention.
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128unique National Health Service numbers to govern-
ment mortality records for patients in England and
Wales. Mortality tracking is not currently performed
for patients from Scotland or Northern Ireland.
STUDY POPULATION. Study subjects were those pa-
tients on the database who underwent a primary PCI
procedure for STEMI in England and Wales between
January 1, 2006, and December 31, 2013. This time
period was chosen to commence after the publication
of small positive clinical trials on thrombectomy but
before publication of the TAPAS study. It extends
forward to include the most recent available BCIS-
NICOR validated data.
OUTCOME MEASURES. The primary outcome mea-
sure for this study was 30-day mortality. The sec-
ondary endpoint was 1-year mortality. These were
selected on the basis of the predicted time frame of
beneﬁt from the active intervention (thrombectomy)
and the design and ﬁndings of foregoing RCTs. Other
secondary endpoints were in-hospital incidence of
reinfarction and of stroke.
STUDY GROUPING. Patients were divided into 2
groups, on the basis of use of a thrombectomy
catheter during the PPCI, versus no such use, as
indicated on the registry. Where a thrombectomy
catheter is passed into the coronary artery, its use is
recorded on the database, regardless of whether the
culprit lesion was successfully reached and of the
amount of thrombus retrieved from the device—
hence coding is on an intention-to-treat basis. The
thrombectomy group was further subclassiﬁed as
simple or complex. Simple (manual) thrombectomyprocedures were those that involved any of the
following (aspiration) devices: Pronto (Vascular Solu-
tions Inc., Minneapolis, Minnesota), Hunter (IHT Cor-
dynamic, Barcelona, Spain), Eliminate (Terumo
Europe, Leuven, Belgium), Export (Medtronic, Min-
neapolis, Minnesota), Quickcat (Spectranetics Inc.,
Colorado Springs, Colorado), Thrombcat (Kensay Nash
Corp., Exton, Pennsylvania), and Diver (Invatec, Ron-
cadelle, Italy). Procedures were coded as complex
thrombectomy if they used any of the following de-
vices: X-sizer (eV3 Endovascular Inc., Plymouth, Min-
nesota), Angiojet (Boston Scientiﬁc Inc., Marlborough,
Massachusetts), Acolysis (Vascular Solutions Inc.,
Minneapolis, Minnesota), and TEC (Interventional
Technologies, Inc., San Diego, California).
STATISTICAL ANALYSIS. Statistical analysis was
performed using Stata v13.1 (College Station, Texas).
Patients who did not have PPCI or did not have their
procedure in England or Wales or had missing infor-
mation regarding critical variables for the analysis
(thrombectomy use, mortality at 30 days, age, or sex)
were excluded.
Descr ipt ive stat i st i cs . For basic analyses of de-
mographics, procedural details, and unadjusted out-
comes, continuous variables were evaluated as
mean  SD. Means, SDs, and percentages quoted for
unadjusted data refer to numbers within the cohort
for which data were available. Chi-square tests were
used to assess the signiﬁcance of differences in pro-
portions between groups for categorical variables.
One-way analysis of variance was used for continuous
variables. All statistical tests were 2-tailed, and an
alpha of 5% (for signiﬁcance) was used throughout.
Multiple imputation for missing data. To reduce poten-
tial bias created by missing data, multiple imputation
methods were used, through the mi impute proce-
dure on Stata. Chained equations were used to
impute data for all variables with missing information
and also included complete variables (age, sex, year
of procedure, thrombectomy type) to generate 10
datasets for use in the analyses.
Var iab les inc luded in model ing . Variables of in-
terest were selected to encompass known or potential
predictors of 30-day mortality, and thus involved:
age, sex, diabetes, hypertension, hyperlipidemia,
smoking status, cerebrovascular disease (previous
stroke), peripheral vascular disease, renal impair-
ment (deﬁned here as serum creatinine>200 mmol/l
or on dialysis), cardiogenic shock, previous MI, pre-
vious PCI, previous coronary artery bypass grafting
(CABG), pre-procedural Thrombolysis In Myocardial
Infarction (TIMI) ﬂow grade, and procedural details
(year of procedure, route of vascular access, use
of aspirin/clopidogrel/prasugrel/ticagrelor, use of
FIGURE 2 Temporal Patterns in Thrombectomy Use
(A) Changes in use of thrombectomy over time in percutaneous coronary intervention (PCI).
The increase in thrombectomy use in primary PCI in the United Kingdom in recent years is
shown. Possible reasons are discussed further in the text. (B) Annual ﬁgures for use of simple
(manual) and complex (mechanical) thrombectomy devices. It is seen that simple (aspiration)
thrombectomy accounts for the majority of thrombectomy used. By contrast, the overall
number of cases of complex thrombectomy remains small although it has increased.
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129glycoprotein IIb/IIIa inhibitor, type of thrombectomy
device, that is, simple aspiration or complex me-
chanical, use of embolic protection device, use of
circulatory support including intra-aortic balloon
pump) and requirement for ventilator support. Stent
type (drug-eluting vs. bare-metal) was also included
because it may be considered as a surrogate marker
for unrecorded comorbidities, and its use as a covar-
iate within the model should help to mitigate the
inﬂuence of unmeasured confounders.
Propens i ty score–based analyses . To better con-
trol for the baseline differences across the groups,
multiple imputation propensity score matching (mi
estimate: teffects psmatch on Stata) was used to esti-
mate the average treatment effect. The method used
all the predictors previously mentioned in 3 separate
multiple imputation logistic regression models
(thrombectomy vs. none; simple vs. none; complex vs.
none), calculating propensity scores for group mem-
bership. Standard settings for the matching algorithm
were used. A minimum of 1 neighbor was requested,
and all observations were considered as potential
matches regardless of how dissimilar their propensity
scores were. Tolerance for the overlap assumptions
was set to 105. Simple logistic regression models
were run (the only predictor being group membership)
to obtain the average treatment effect.
Sensitivity analyses were performed with fully
adjusted (multiple) logistic regression. Multiple
imputation logistic regressions (mi estimate: logistic
on Stata), which included the propensity score as a
covariate, were used to calculate adjusted odds of 30-
day mortality for overall thrombectomy use versus
none, simple thrombectomy versus none, and com-
plex thrombectomy versus none. We performed 2
additional sensitivity analyses, the ﬁrst limited to
patients with left ventricular ejection fraction data
and controlled for them, the second considering only
participants with the left anterior descending coro-
nary artery as the infarct-related artery.RESULTS
Figure 1 provides a ﬂowchart indicating exclusions
and hence the numbers available for unadjusted and
adjusted statistical analyses. A total of 107,549 pa-
tients underwent primary PCI from 2005 to 2013 in
England and Wales, and 98,176 were included in the
analysis. Although multiple imputation was used to
obtain a cohort that was as complete as possible,
there were lower patient numbers in the adjusted
analyses because cases in which critical variables (see
the preceding text) were missing were excluded.Figure 2A demonstrates the changing pattern of
thrombectomy use in PPCI over the study period.
Thrombectomy was used in <5% of cases in 2006. A
rapid uptake of the technique was seen between 2008
and 2010, with a relative plateauing of overall
thrombectomy numbers (i.e., proportional use in
primary PCI) thereafter, at slightly below 50%.
Figure 2B demonstrates that simple aspiration tools
accounted for the majority of devices used, although
there has been a steady year-on-year increase in the
use of complex devices from 2007 until 2012.
Baseline demographics and procedural details for
patients who did and did not receive thrombectomy
are shown in Table 1. Missing data are summarized in
Online Table 1. It is seen that imbalances exist between
the 2 groups in terms of these baseline characteristics,
TABLE 1 Baseline Patient Demographics, Procedural Details, and Unadjusted Outcomes
No Thrombectomy
(n ¼ 59,228)
Thrombectomy
(n ¼ 38,948) p Value
Age, yrs 65  13 62  13 <0.001
Male 43,291 (73) 29,595 (76) <0.001
Smoking status <0.001
Never 17,804 (34) 11,389 (32)
Ex-smoker 14,305 (27) 9,394 (26)
Current 20,207 (39) 15,100 (42)
Diabetes mellitus 8,349 (15) 4,780 (13) <0.001
Hypertension 24,012 (42) 14,845 (38) <0.001
Hypercholesterolemia 22,940 (40) 14,827 (38) <0.001
Peripheral vascular disease 2,019 (4) 1,075 (3) <0.001
Renal disease 1,091 (2) 538 (1) <0.001
Previous myocardial infarction 7,931 (14) 4,089 (11) <0.001
Previous stroke 2,220 (4) 1,331 (3) 0.001
Previous percutaneous
coronary intervention
5,283 (9) 3,376 (9) 0.061
Previous coronary artery bypass graft 16,040 (27) 14,055 (36) <0.001
Left ventricular ejection fraction <0.001
$50% 11,486 (57) 6,162 (53)
31%–49% 6,152 (31) 4,126 (36)
#30% 2,513 (12) 1,306 (11)
Pre-procedure TIMI ﬂow grade <0.001
TIMI 0 31,905 (64) 27,744 (82)
TIMI 1 4,829 (10) 1,949 (6)
TIMI 2 5,892 (12) 2,128 (6)
TIMI 3 7,537 (15) 1,816 (5)
Cardiogenic shock 4,112 (7) 2,757 (7) 0.585
Ventilatory support 2,159 (4) 1,313 (4) 0.304
Circulatory support 2,830 (5) 2,037 (5) <0.001
Glycoprotein IIb/IIIa inhibitors 27,778 (49) 20,280 (55) <0.001
Antiplatelet therapy <0.001
Clopidogrel 33,664 (78) 17,180 (64)
Prasugrel 7,220 (17) 6,616 (25)
Ticagrelor 2,408 (6) 3,104 (12)
Bivalirudin 5,025 (9) 6,991 (19) <0.001
Embolic protection device 213 (0.4) 294 (0.8) <0.001
Stent <0.001
None 4,898 (8) 2,373 (6)
Bare-metal 29,104 (50) 14,917 (39)
Drug-eluting 24,661 (42) 21,426 (55)
Radial access 27,179 (47) 24,868 (64) <0.001
Vessel attempted
Venous or arterial graft 1,143 (2) 666 (2) 0.011
Left main stem artery 1,499 (3) 749 (2) <0.001
Left anterior descending artery 26,361 (45) 16,387 (42) <0.001
Left circumﬂex artery 10,229 (17) 5,420 (14) <0.001
Right coronary artery 24,134 (41) 17,482 (45) <0.001
Continued on the next page
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130although no consistent direction of bias is evident. For
example, patients who did not receive thrombectomy
tended to be slightly older, more likely to be female,
and have diabetes, hypertension, hypercholesterole-
mia, peripheral vascular disease, or previous MI. Pa-
tients who did receive thrombectomywere more likely
to be current smokers, have had prior CABG, to presentwith pre-procedural TIMI ﬂow grade 0, and to need
circulatory support (with inotropes or intra-aortic
balloon pumping). In terms of P2Y12 receptor antago-
nists, clopidogrel was the most commonly used agent
in both groups, but both prasugrel and ticagrelor were
used to a greater extent in those patients who received
thrombectomy. Additionally, glycoprotein IIb/IIIa
inhibitors, bivalirudin, and drug-eluting stents were
used more often in patients with thrombectomy. Pa-
tients in the thrombectomy group also had a shorter
mean symptom-to-balloon time. Crude mortality at
both 30 days and 1 year was seen to be signiﬁcantly
lower in those who received thrombectomy compared
with those who did not. There were no differences
between groups in reinfarction or incident stroke
rates. Online Table 2 shows a comparison of de-
mographics and procedural variables according to no
thrombectomy versus simple thrombectomy versus
complex thrombectomy.
Table 2 shows the propensity score–matched re-
sults comparing use of thrombectomy and no
thrombectomy. It was seen that, when comparison
between matched pairs was undertaken, no signiﬁ-
cant difference in all-cause mortality (at 30 days or at
1 year) remained between the 2 groups (thrombec-
tomy vs. no thrombectomy). Table 2 shows a sub-
group analysis of simple thrombectomy compared
with no thrombectomy. Simple (manual) thrombec-
tomy was not associated with any signiﬁcant differ-
ence in mortality at either time point. However, with
complex thrombectomy, no mortality difference was
observed at 30 days, but there was a signiﬁcant in-
crease in mortality by 1 year (p ¼ 0.017) (Online
Table 3). The area under the receiver operator
curves for these analyses are shown in Table 2. The
balance diagnostics for this propensity matching
model and the quality of matching are presented in
Online Table 4.
This relationship was explored further through
sensitivity analysis incorporating the propensity score
as a covariate in a fully adjusted multiple logistic
regression (Table 3). This showed similar ﬁndings to
the propensity score–matched results, namely com-
plex thrombectomy being associated with a trend to
highermortality (comparedwith no thrombectomy) by
30 days (p ¼ 0.063) and a signiﬁcant difference at
the 1-year time point (p ¼ 0.026). None of the other
comparisons between groups in the sensitivity anal-
ysis showed statistically signiﬁcant differences.
We performed additional analyses with adjust-
ments for left ventricular ejection fraction and only
considering participants that had the left anterior
descending coronary artery as the infarct-related ar-
tery. These results are shown in Online Tables 5
TABLE 1 Continued
No Thrombectomy
(n ¼ 59,228)
Thrombectomy
(n ¼ 38,948) p Value
Post-procedure TIMI ﬂow grade <0.001
TIMI 0 3,854 (8) 955 (3)
TIMI 1 747 (1) 349 (1)
TIMI 2 2,474 (5) 1,855 (5)
TIMI 3 43,333 (86) 30,810 (91)
Symptom to balloon time, h 4.6  3.9 4.2  3.5 <0.001
Year <0.001
2006 2,621 (4) 122 (0.3)
2007 4,185 (7) 285 (0.7)
2008 5,862 (10) 1,310 (3)
2009 7,334 (12) 3,880 (10)
2010 8,162 (14) 6,719 (17)
2011 9,845 (17) 8,280 (21)
2012 10,951 (18) 9,176 (24)
2013 10,268 (17) 9,176 (24)
Reinfarction (during index admission) 108 (0.2) 57 (0.2) 0.197
Stroke (during index admission) 157 (0.3) 116 (0.3) 0.303
30-Day mortality 3,863 (7) 2,142 (6) <0.001
1-Year mortality 6,123 (11) 3,289 (9) <0.001
Values are mean  SD for age and for symptom-to-balloon time; for remaining variables, values are n(%), where
n denotes absolute number of cases and % indicates this as a percentage of all cases for which data was available
for that variable.
TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 2 Propensity Score Matching Analysis on 10 Imputed Datasets,
Reporting ATE, and Area Under ROC Curve*
N Coefﬁcient
95% Conﬁdence
Interval p Value
Any vs. no thrombectomy†
30-day mortality 98,176 0.0028 0.0048 0.0104 0.465
1-yr mortality 90,376 0.0057 0.0027 0.0140 0.181
Simple vs. no thrombectomy†
30-day mortality 92,793 0.0007 0.0049 0.0063 0.802
1-yr mortality 85,675 0.0023 0.0072 0.0118 0.628
Any vs. No Thrombectomy Simple vs. No Thrombectomy
Average ROC curve‡ 0.746 0.749
*Adjusted for age, sex, smoking status, year of PCI, previous PCI, previous CABG, previous
myocardial infarction, diabetes, hypercholesterolemia, hypertension, peripheral vascular disease,
previous stroke, renal disease, cardiogenic shock, receipt of ventilation, circulatory support, use of
glycoprotein IIb/IIIa inhibitors, use of bivalirudin, antiplatelet use, radial access site, embolic
protection device, left main stem disease, graft disease, type of stent, pre-procedure TIMI ﬂow,
balloon time, in-hospital reinfarction, and in-hospital stroke. †Each case was matched to at least 1
control patient, and each control patient was matched to at least 1 case (matching with
replacement). ‡Across the 10 imputed datasets.
ATE ¼ average treatment effects; ROC ¼ receiver-operating characteristic.
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131and 6, respectively, and the results are similar to
those of previous analyses.
DISCUSSION
The role of coronary thrombectomy in PPCI for STEMI
has been controversial. An appealing biological ratio-
nale, coupled with encouraging early trial results,
fueled its uptake over the early part of the last decade.
Now, in thewake of 2 large RCTs that failed to showany
important clinical beneﬁts, its place in our therapeutic
armamentarium is unclear. This uncertainty is inten-
siﬁed by safety concerns with thrombectomy, partic-
ularly in relation to increased risk of stroke (8,12).
However, one central unanswered question, notwith-
standing results from the TASTE and TOTAL studies, is
whether there may yet be a relevant impact on mor-
tality that these RCTs were not able to identify. This is
certainly plausible, given the size of studies required
to demonstrate the survival beneﬁts of other STEMI
therapies such as aspirin and thrombolysis (more than
17,000 patients in the ISIS-2 study (Second Interna-
tional Study of Infarct Survival) to show a relative risk
reduction of 20% to 25%) (13). A smaller (but still
clinically meaningful) effect with thrombectomy may
require a much larger sample size than that to be
detectable. Our BCIS cohort comprised over 98,000
STEMI cases (compared with around 7,000 in the
TASTE study and around 10,700 in the TOTAL study),
yielding more statistical power to study the associa-
tion between thrombectomy use and mortality—albeit
within the constraints of observational data and in the
context of selective, rather than routine, thrombec-
tomy use. Our data represent by far the largest pub-
lished series addressing this issue.
PATTERNS OF PRACTICE. Our data illustrate the
temporal patterns in thrombectomy use in the United
Kingdom. Some of the sharp increase in uptake seen
after 2008 may relate to the high-proﬁle publication
of ﬁndings from the TAPAS trial, possibly persuading
previously skeptical operators. However, a leveling
out of uptake is seen after 2010, with proportionate
use running at slightly <50% of all PPCI cases. The
explanation for this observed plateau may relate to
physician judgments on both efﬁcacy and safety of
thrombectomy in individual cases. Regarding
efﬁcacy, operator decisions may incorporate the
angiographically visible thrombus burden (with
thrombectomy being omitted in cases with less
marked thrombus, if gains are perceived to be
limited). Thrombus burden is not coded as a ﬁeld on
the BCIS-NICOR dataset, so the decision to use
thrombectomy could not be correlated to this index.
Surprising ﬁndings from the TOTAL study suggestthat high TIMI thrombus grade might not in fact
delineate a group in which thrombectomy is of
particular beneﬁt; however, because the study was
not powered for this subgroup analysis, this ﬁnding
should be considered as hypothesis generating.
Other potential limitations to thrombectomy up-
take relate to individualized safety concerns—for
example, when coronary anatomic factors suggest
TABLE 3 Sensitivity Analysis, by Multiple Logistic Regression
Incorporating the Propensity Score as a Covariate in the Model
Adjusted by
Propensity Score* N
Odds Ratio
(95% Conﬁdence Interval) p Value
30-day mortality
Thrombectomy vs. no
thrombectomy
98,176 1.02 (0.96–1.08) 0.608
1-yr mortality
Thrombectomy vs. no
thrombectomy
90,376 1.02 (0.97–1.07) 0.452
30-day mortality
Simple vs. no
thrombectomy
92,793 1.00 (0.93–1.06) 0.889
1-yr mortality
Simple vs. no
thrombectomy
85,675 1.00 (0.95–1.05) 0.955
*Adjusted for age, sex, smoking status, year of percutaneous coronary intervention
(PCI), previous PCI, previous coronary artery bypass grafting, previous myocardial
infarction, diabetes, hypercholesterolemia, hypertension, peripheral vascular dis-
ease, previous stroke, renal disease, cardiogenic shock, receipt of ventilation,
circulatory support, use of glycoprotein IIb/IIIa inhibitors, use of bivalirudin,
antiplatelet use, radial access site, embolic protection device, left main stem
disease, graft disease, type of stent, pre-procedure Thrombolysis In Myocardial
Infarction ﬂow grade, balloon time, in-hospital reinfarction, and in-hospital stroke.
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132likely difﬁculties with thrombectomy use—this could
include upstream coronary disease, calciﬁed or highly
tortuous vessels, and small caliber or distally located
culprit-lesion locations. All of these situations can
potentially prevent delivery of the device to the
culprit lesion and create concomitant risks of vessel
wall injury. These relative contraindications were, in
effect, already factored into the TASTE trial, where
randomization was undertaken after angiographic
results were known, and hence patients with signiﬁ-
cant anatomic complexities were very likely to have
been excluded. This caveat does not apply to the
TOTAL trial. However, in real-life practice, many op-
erators will be highly reluctant to use thrombectomy
in cases of unfavorable anatomy. For these reasons,
clinical outcomes from cases where physicians
voluntarily performed thrombectomy (rather than
being mandated to perform it by a trial protocol) are
of great practical relevance.
KEY FINDINGS FROM THE BCIS-NICOR REGISTRY.
Our unadjusted (raw) data demonstrated a lower
mortality in the thrombectomy group, but nonrandom
treatment allocation severely limits any conclusions
from this. Hence, propensity-based adjustment was
used to balance groups—our principal analysis (by
matching) and the sensitivity analysis concurred in
ﬁnding no signiﬁcant evidence of lower mortality with
selective use of thrombectomy at either 30 days or 1
year. This held true for both the overall thrombectomy
group and for the simple (manual aspiration) group.
(Central Illustration). Furthermore, no advantage tothrombectomy emerged even when only patients with
a left anterior descending coronary artery culprit
lesion were studied. Our ﬁndings are thus consistent
with the message emerging from the routine manual
thrombectomy approach tested in the TASTE and
TOTAL studies. It appears that, even when used more
selectively in an all-comer STEMI population, manual
thrombectomy was not associated with a survival
advantage.
The group of patients who received complex
(mechanical) thrombectomy deserve additional
consideration. They were seen to have higher mor-
tality in both of our adjusted analyses. Review of
their baseline characteristics (Online Table 2) does
not suggest a group who were more unwell at base-
line compared with other subjects. The indication for
choosing complex (mechanical) thrombectomy is not
captured on our database and hence to comment is
speculative. However, it is plausible that use of me-
chanical thrombectomy might be more likely in cases
with massive or recalcitrant thrombus, or where
preceding efforts during the case had failed to obtain
a good result in terms of restoring ﬂow. Hence, these
patients may not have been more unwell by virtue of
database-captured baseline indices but may never-
theless have been at higher risk on the basis of
angiographic appearances or the response to initial
treatment. These factors might therefore underlie the
higher mortality found in this group. An alternative
explanation could involve a higher risk of complica-
tions speciﬁcally related to the mechanical throm-
bectomy device; however, this would run contrary to
the ﬁndings of the larger RCTs in which such complex
devices have been studied.
STUDY LIMITATIONS. First, the U.K. national PCI
database does not currently record the reasons
underlying the use (or nonuse) of thrombectomy
devices, and hence, it is not possible to distinguish
between those on the basis speciﬁc culprit lesion
factors (e.g., heavy thrombus load), other anatomic
factors (e.g., calciﬁc tortuous vessels), or simply
physicians’ default preferences. These possible un-
derlying reasons (some of which may potentially in-
ﬂuence both treatment allocation and clinical
outcome) therefore represent unmeasured con-
founders in this work. Similarly, reasons behind the
choice between manual aspiration versus complex
mechanical thrombectomy are not captured, and the
same confounders may be present.
Second, there weremany patients withmissing data
regarding left ventricular ejection fraction, which is an
important determinant of survival (14). This has been
addressed in part by exclusion of this variable from the
CENTRAL ILLUSTRATION Plots of Overall Thrombectomy, Simple Thrombectomy, and Complex Thrombectomy,
Each Compared to No Thrombectomy, With Regard to Mortality
Average treatment effects calculated from our principal analysis (propensity score matching) are indicated. Mortality at 30-day and 1-year time
points is shown in the upper and lower, respectively. CI ¼ conﬁdence interval.
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133principal analysis and by use of a sensitivity analysis in
which left ventricular ejection fraction was included,
with similar outcomes recorded. Third, we do not have
data on the speciﬁc complication of stent thrombosis,
although this is relevant in examining the possible
value of thrombectomy.
CONCLUSIONS
Our large observational study does not provide
evidence to support the hypothesis that selectivethrombectomy in primary PCI is associated with
lower mortality. Our ﬁndings are in keeping with
other negative clinical outcomes from 2 recent
large RCTs studying routine thrombectomy use in
STEMI.
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PERSPECTIVES
WHAT IS KNOWN? Coronary thrombectomy has been
frequently used in primary PCI for STEMI. However, recent
large randomized trials have shown no signiﬁcant advan-
tages in clinical outcome measures with its use, but
increased risks, particularly stroke. However, these trials
were not adequately powered to examine an inﬂuence on
mortality. Additionally, the potential beneﬁt of using
thrombectomy in a more selective manner (on the basis of
physician choice), rather than routinely, remains unclear.
WHAT IS NEW? This study examined mortality in over
98,000 patients treated with PPCI for STEMI in the
United Kingdom between 2006 and 2013. The ﬁndings
indicate no evidence of improved survival (at 30 days or
1 year) in patients treated with thrombectomy, at
physician discretion, for STEMI. These results are
consistent with a lack of improvement in other clinical
indices in recent large RCTs of routine aspiration
thrombectomy in STEMI.
WHAT IS NEXT? Future work should focus on alterna-
tive strategies to minimize reperfusion injury and micro-
vascular dysfunction during and after primary PCI for
STEMI.
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